About the study

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.
2. Female participants must agree to contraception requirements.

Exclusion criteria

1. Participants must not have developed a new condition, including cancer in the originator study.
2. Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study
3. Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
4. Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.